Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine

Detalles Bibliográficos
Autores principales: Haslem, Derrick S., Ji, Hanlee P., Ford, James M., Nadauld, Lincoln D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446358/
https://www.ncbi.nlm.nih.gov/pubmed/32913966
http://dx.doi.org/10.1200/PO.16.00055
_version_ 1783574142172266496
author Haslem, Derrick S.
Ji, Hanlee P.
Ford, James M.
Nadauld, Lincoln D.
author_facet Haslem, Derrick S.
Ji, Hanlee P.
Ford, James M.
Nadauld, Lincoln D.
author_sort Haslem, Derrick S.
collection PubMed
description
format Online
Article
Text
id pubmed-7446358
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-74463582020-09-09 Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine Haslem, Derrick S. Ji, Hanlee P. Ford, James M. Nadauld, Lincoln D. JCO Precis Oncol Case Reports American Society of Clinical Oncology 2017-06-27 /pmc/articles/PMC7446358/ /pubmed/32913966 http://dx.doi.org/10.1200/PO.16.00055 Text en © 2017 by American Society of Clinical Oncology http://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
spellingShingle Case Reports
Haslem, Derrick S.
Ji, Hanlee P.
Ford, James M.
Nadauld, Lincoln D.
Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
title Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
title_full Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
title_fullStr Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
title_full_unstemmed Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
title_short Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
title_sort precision oncology strategy in trastuzumab-resistant human epidermal growth factor receptor 2–positive colon cancer: case report of durable response to ado-trastuzumab emtansine
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446358/
https://www.ncbi.nlm.nih.gov/pubmed/32913966
http://dx.doi.org/10.1200/PO.16.00055
work_keys_str_mv AT haslemderricks precisiononcologystrategyintrastuzumabresistanthumanepidermalgrowthfactorreceptor2positivecoloncancercasereportofdurableresponsetoadotrastuzumabemtansine
AT jihanleep precisiononcologystrategyintrastuzumabresistanthumanepidermalgrowthfactorreceptor2positivecoloncancercasereportofdurableresponsetoadotrastuzumabemtansine
AT fordjamesm precisiononcologystrategyintrastuzumabresistanthumanepidermalgrowthfactorreceptor2positivecoloncancercasereportofdurableresponsetoadotrastuzumabemtansine
AT nadauldlincolnd precisiononcologystrategyintrastuzumabresistanthumanepidermalgrowthfactorreceptor2positivecoloncancercasereportofdurableresponsetoadotrastuzumabemtansine

Ejemplares similares